Trending

Xalkori

Will new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?

Will new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?

Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug

X

Will new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?

https://pharmaphorum.com/news/will-new-data-make-pfizers-lorbrena-a-no-brainer-in-early-lung-cancer/

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a

X

Takeda sets sights on first-line lung cancer market with new Alunbrig data

https://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

X

NICE recommends Pfizer’s Xalkori in rare lung cancer

https://pharmaphorum.com/news/nice-pfizers-xalkori-rare-lung-cancer/

Xalkori gains NICE approval after price cut

Xalkori gains NICE approval after price cut

NICE approval secured against background of renewed controversy

X

Xalkori gains NICE approval after price cut

https://pharmaphorum.com/news/xalkori-gains-nice-approval-price-cut/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com